

For Immediate release

31st April 1, 2017

FROM: Board of Directors

SUBJECT: Resignation of Steve Drew Director & Group CEO

It is with a mix of sadness and gratitude that the Board of Directors announce Steve Drew's departure as Director & Group CEO. Since 2008, Steve has played a critical role in the development and success of the Bioven organisation, and while we will miss him and his inspiring leadership, we wish him the best of luck in future career endeavors. We want to thank Steve for the 9 years of dedicated service which involved many significant accomplishments, including :

- Recruiting a team of experienced pharma executives
- implementing a business strategy that has resulted in :
 - An ongoing pivotal global Phase III trial (including US FDA clearance to initiate planned US site participation)
 - A strong cancer immunotherapy R&D program and pipeline projects
 - the establishment of a global independent KOL's / advisors board
 - Key strategic partnerships to support Bioven's business objectives

Over the next few months, we will be conducting a search to find the new Bioven CEO. During this transition period, it is our priority to find the best individual to lead, while still maintaining a stable and effective organization. Johan Indot, Executive Deputy Chairman will take over directing day to day operations with the management of Senior team, whom will report directly to him until further notice.

If you have any questions, please contact Johan Indot at johan@bioven.com

Sincerely,

Tan Sri Dato' Dr. Abu Bakar Suleiman,
Chairman, Board of Directors, Bioven Group

About Bioven:

Bioven is a late-stage biopharmaceutical company focused on the treatment of cancer. Its strategy is to in-license compounds and develop them through late-stage clinical trials prior to out-licensing to major healthcare or specialty pharma companies.

Bioven's most advanced compound is EGF-PTI, a novel immunotherapy for non-small cell lung cancer (NSCLC), which is currently in an International Phase III trials.

Bioven is a privately held company founded in 2002 in Malaysia and with offices in the UK and Kuala Lumpur. For further information, please visit www.bioven.com